Following a sharp decline in tech stocks, the October jobs report is expected to provide either relief or further disappointment for investors. Although more industries beyond healthcare are hiring, the overall number of new jobs created remains very low. This suggests the labor market is improving unevenly and may not significantly boost investor confidence. Market watchers will closely analyze the report released Friday morning for signs of economic strength or weakness.
The October jobs report and recent tech-stock rout provide context for market conditions. For readers following US stocks, here is Pluang's market snapshot as of Nov 06, 2026 01:11 WIB: Of 150 priced US stocks tradable on Pluang, 20 rose and 130 fell today. Notable movers include AMAT at USD 327.15 with a 1-day change of -11.44%, TSLA at USD 341.25 with -11.41%, and CGC at USD 0.67 with -10.55%.
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Following Binance's $6.3 billion hack, the Federal Reserve and the Office of the Comptroller of the Currency (OCC) have contacted U.S. banks to inquire about any unusual activity, service disruptions, or system vulnerabilities. This oversight aims to...
Windward Bio Group AG plans to raise over $100 million through a U.S. IPO to support the development of its clinical-stage asthma drug, WIN378, which has shown promising Phase 2/3 results. The company expects pivotal trial data by mid-2027 and target...
